Published in Risk Manag Healthc Policy on March 08, 2012
Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy. Hum Vaccin Immunother (2013) 0.81
Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med (2001) 51.99
Meningococcal disease. N Engl J Med (2001) 8.50
Clinical recognition of meningococcal disease in children and adolescents. Lancet (2006) 6.27
Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet (1999) 6.02
Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol (2001) 5.43
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (2007) 5.11
Meningococcal disease: still with us. Rev Infect Dis (1983) 4.36
Global epidemiology of meningococcal disease. Vaccine (2009) 4.26
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2005) 4.15
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Emergency management of meningococcal disease. Arch Dis Child (1999) 3.93
Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev (2000) 3.69
"Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet (1997) 3.68
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis (2010) 3.61
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine (2001) 3.36
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet (2001) 3.19
The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA (1995) 3.09
Efficacy of meningococcal vaccine and barriers to vaccination. JAMA (1998) 2.92
Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA (1990) 2.79
Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev (2007) 2.78
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
A review of vaccine research and development: meningococcal disease. Vaccine (2006) 2.64
Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics (2001) 2.62
Health disparities experienced by black or African Americans--United States. MMWR Morb Mortal Wkly Rep (2005) 2.58
Clinical practice. Prevention of meningococcal disease. N Engl J Med (2006) 2.53
The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. BMJ (2005) 2.52
Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 2.50
Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study. BMJ (1998) 2.41
Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol (1991) 2.38
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ (2003) 2.30
Acute bacterial meningitis in infants and children. Lancet Infect Dis (2010) 2.30
Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA (1997) 2.29
Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis (2003) 2.16
Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet (1999) 1.93
Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA (2001) 1.88
Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis (1997) 1.86
Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis (1998) 1.86
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Guidelines for public health management of meningococcal disease in the UK. Commun Dis Public Health (2002) 1.79
Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol (2002) 1.77
Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun (2004) 1.59
Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med (2005) 1.58
Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep (2011) 1.54
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine (2009) 1.52
Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in Niger. Trans R Soc Trop Med Hyg (2005) 1.50
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2000) 1.49
Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis (2003) 1.49
Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med (1999) 1.47
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis (2010) 1.31
School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JAMA (1997) 1.28
Multicenter surveillance of invasive meningococcal infections in children. Pediatrics (2006) 1.27
Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect (2011) 1.27
Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ (2006) 1.21
The orthopaedic management of peripheral ischaemia in meningococcal septicaemia in children. J Bone Joint Surg Br (2000) 1.20
Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine (2005) 1.17
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J (2006) 1.14
Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1997) 1.14
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J (2007) 1.13
Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun (2003) 1.12
Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J (2000) 1.05
Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. J Clin Invest (1980) 1.04
Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect (2005) 1.03
The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz (1999) 1.02
Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. Can J Microbiol (2003) 1.01
Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA (2004) 1.01
Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res (2010) 1.00
Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch Dis Child (2001) 0.99
[Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Rev Panam Salud Publica (2008) 0.99
Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis (2011) 0.98
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol (2004) 0.97
Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep (2009) 0.96
Complications of meningococcal disease in college students. Clin Infect Dis (2001) 0.95
[Meningococcal disease caused by Neisseria meningitidis: epidemiological, clinical, and preventive perspectives]. Salud Publica Mex (2004) 0.95
Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers? Int J Epidemiol (2006) 0.95
Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002-2004. Clin Infect Dis (2009) 0.94
Use of meningococcal vaccines in the United States. Pediatr Infect Dis J (2007) 0.91
Mortality in meningococcal disease: please report the figures accurately. Arch Dis Child (2002) 0.91
Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application. MEDICC Rev (2007) 0.90
Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J (2010) 0.88
Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine (2000) 0.88
The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine (2005) 0.86
Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr (2010) 0.85
Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients. Intensive Care Med (2004) 0.85
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol (2006) 0.85
Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics (2009) 0.84
Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol (2009) 0.83
Differing mechanisms of early and late B cell hyporesponsiveness induced by mixed chimerism. Am J Transplant (2005) 0.82
Maternal and infant antibody response to meningococcal vaccination in pregnancy. Lancet (1977) 0.82
Orthopaedic sequelae of childhood meningococcemia: management considerations and outcome. J Bone Joint Surg Am (2010) 0.80
Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Hum Vaccin (2006) 0.80
Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome. Shock (2000) 0.79
Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine (2003) 0.79
Minimizing limb amputations in meningococcal sepsis by early microsurgical arteriolysis. J Pediatr Surg (2009) 0.78
Meningococcal disease and meningitis. J Pediatr (Rio J) (2007) 0.78
[Epidemiology of the meningococcal disease in Catalonia before and after vaccination against serogroup C]. Rev Esp Salud Publica (2010) 0.77
Management and Treatment Guidelines for Sepsis in Pediatric Patients. Open Inflamm J (2011) 0.76